Evidence map›Paper›PMID 41758293›Full record

ArticleTargeted oncology2026

Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab.

Silvia Camera, Lorenzo Fornaro, Margherita Rimini, Mara Persano, Mario Domenico Rizzato, Anna Saborowski, Lorenzo Antonuzzo, Federico Rossari, Tomoyuki Satake, Frederik Peeters and 66 more

Abstract read
PubMed Publisher
In one paragraph

Article in Targeted oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

76 authors.

Silvia Camera *Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.ORCID http://orcid.org/0000-0001-8203-1684
Lorenzo Fornaro *Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. lorenzo.fornaro@gmail.com.
Margherita Rimini *Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
Mara PersanoDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
Mario Domenico RizzatoDepartment of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Anna SaborowskiHannover Medical School, Hannover, Germany.
Lorenzo AntonuzzoClinical Oncology Unit, Careggi University Hospital, Florence, Italy.
Federico RossariDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
Tomoyuki SatakeDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Frederik PeetersDigestive Oncology, University Hospitals Leuven, Leuven, Belgium.
Francesca SalaniUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Silvia BozzarelliMedical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Salvatore CoralloInternal Medicine and Medical Therapy Department, University of Pavia, Pavia, Italy.
Jessica LucchettiOperative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200-00128, Rome, Italy.
Jin Won KimDivision of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, Republic of Korea.
Oluseyi AbidoyeDepartment of Internal Medicine, Mayo Clinic, Phoenix, AZ, USA.
Ilario Giovanni RapposelliDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Chiara GallioDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Stefano TamberiMedical Oncology, Santa Maria delle Croci Hospital, Ravenna AUSL Romagna, Ravenna, Italy.
Fabian FinkelmeierMedical Clinic 1, Department of Gastroenterology, University Hospital Frankfurt, Frankfurt am Main, Germany.
Guido GiordanoUnit of Medical Oncology and Biomolecular Therapy, Policlinico Riuniti, Foggia, Italy.
Pircher ChiaraDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Hong Jae ChonDivision of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.
Chiara BraconiUniversity of Glasgow (School of Cancer Sciences), Beatson West of Scotland Cancer Centre, CRUK Scotland Centre, Glasgow, UK.
Aitzaz QaisarUniversity of Glasgow (School of Cancer Sciences), Beatson West of Scotland Cancer Centre, CRUK Scotland Centre, Glasgow, UK.
Alessandro PastorinoIRCCS Ospedale Policlinico San Martino, Medical Oncology Unit 1, Genoa, Italy.
Florian CastetGastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Emiliano TamburiniOncology Department and Palliative Care, Cardinale Panico Tricase City Hospital, 73039, Tricase, Italy.
Changhoon YooASAN Medical Center, University of Ulsan College of Medicine, Ulsan, Republic of Korea.
Alessandro ParisiClinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126, Ancona, Italy.
Anna DianaOncology Unit, Ospedale del Mare, Naples, Italy.
Mario ScartozziMedical Oncology, University and University Hospital, Cagliari, Italy.
Gerald W PragerDepartment of Medicine I, Clinical Division of Oncology, Medical University Vienna, Vienna, Austria.
Antonio AvalloneClinical Experimental Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, 80131, Naples, Italy.
Marta SchirripaMedical Oncology Unit, Department of Oncology and Hematology, Belcolle Hospital, Viterbo, Italy.
Il Hwan KimDivision of Oncology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
Lukas PerkhoferInternal Medicine 1, University Hospital Ulm, Ulm, Germany.
Ester OnedaDipartimento di Oncologia Medica, Fondazione Poliambulanza, Brescia, Italy.
Monica VerricoUOC Oncologia A, Department of Hematology, Oncology and Dermatology, Policlinico Umberto I University Hospital, Sapienza University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy.
Nuno CoutoDigestive Unit, Champalimaud Clinical Centre, Champalimaud Research Centre, Lisbon, Portugal.
Jorge AdevaMedical Oncology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain.
Stephen L ChanState Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Gian Paolo SpinelliUOC Oncologia Territoriale, Polo Pontino, La Sapienza Università Di Roma, Latina, Italy.
Nicola PersoneniMedical Oncology Unit, P.O. Manerbio-ASST Garda, 25025, Manerbio, Brescia, Italy.
Ingrid GarajovaMedical Oncology Unit, University Hospital of Parma, 43126, Parma, Italy.
Maria Grazia RodriquenzOncology Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy.
Silvana LeoDivision of Oncology, Vito Fazzi Hospital, Lecce, Italy.
Cecilia Melo AlvimMedical Oncology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, 1649-035, Lisbon, Portugal.
Ricardo RoquePortuguese Institute of Oncology of Coimbra, 3000-075, Coimbra, Portugal.
Giovanni FarineaMedical Oncology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain.
Virginia GenovesiUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Antonio De RosaDepartment of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Daniele LavacchiClinical Oncology Unit, Careggi University Hospital, Florence, Italy.
Federica Lo PrinziOperative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200-00128, Rome, Italy.
Laura PasseriDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
Michele FerraraDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
Silvia FotiDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
Masafumi IkedaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Jeroen DekervelDigestive Oncology, University Hospitals Leuven, Leuven, Belgium.
Monica NigerDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Rita BalsanoMedical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Giuseppe ToniniDepartment of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21, 00128, Rome, Italy.
Minsu KangDivision of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, Republic of Korea.
Giulia TesiniDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Luca EspositoDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Chiara CasadioMedical Oncology, Santa Maria delle Croci Hospital, Ravenna AUSL Romagna, Ravenna, Italy.
Vera HimmelsbachMedical Clinic 1, Department of Gastroenterology, University Hospital Frankfurt, Frankfurt am Main, Germany.
Matteo LandriscinaUnit of Medical Oncology and Biomolecular Therapy, Policlinico Riuniti, Foggia, Italy.
Selma Ahcene DjaballahDepartment of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Tanios Bekaii-SaabDepartment of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.
Gianluca MasiUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Arndt VogelHannover Medical School, Hannover, Germany.
Sara LonardiDepartment of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Caterina VivaldiUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Lorenza Rimassa *Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. lorenza.rimassa@hunimed.eu.
Andrea Casadei-Gardini *Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy. casadeigardini@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrently, data concerning the prognostic impact of metastatic sites in biliary tract cancers (BTC) are limited.

objectiveThe aim of the present study is to evaluate the prognostic impact of metastatic sites in patients with BTC treated with cisplatin-gemcitabine-durvalumab (CGD). PATIENTS AND

methodsThe study population comprised a large worldwide cohort of patients treated with CGD. The primary objectives were overall survival (OS) and progression-free survival (PFS) based on the location and number of metastatic sites.

resultsA total of 666 patients with locally advanced (111) or metastatic (555) BTC treated with CGD were included in the study. None of the metastatic sites were shown to have a prognostic impact on OS at multivariate analysis. Patients with one to two metastatic sites had longer OS (hazard ratio [HR] 0.59; p = 0.005) and PFS (HR 0.73; p = 0.03) compared with those with three to five metastatic sites in the univariate analysis but not in the multivariate analysis. No statistically significant differences were observed in OS or PFS across different metastatic sites limited to a single organ. Patients with progressive disease (PD) on first-line CGD with a change in metastatic sites from baseline showed no statistically significant differences in OS2 (defined as the time from PD on first-line therapy to death for any cause) compared with those without a change in metastatic sites (HR 0.88; p = 0.60).

conclusionsOur study did not show statistically significant differences in outcomes associated with location and number of metastatic sites in a large population of patients with BTC treated with CGD.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiliary Tract NeoplasmsCisplatinDeoxycytidineAdultAgedFemaleGemcitabineHumansMaleMiddle AgedNeoplasm MetastasisPrognosisCisplatinDeoxycytidineGemcitabine

Identifiers

PMID41758293

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.